{"id":78798,"date":"2026-09-04T16:44:52","date_gmt":"2026-09-04T08:44:52","guid":{"rendered":"https:\/\/flcube.com\/?p=78798"},"modified":"2026-09-04T16:44:53","modified_gmt":"2026-09-04T08:44:53","slug":"trinomabs-retavibart-wins-nmpa-priority-approval-as-rsv-prevention-monoclonal-antibody-xinduotuo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78798","title":{"rendered":"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Zhuhai Trinomab Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688806:SHA\">SHA: 688806<\/a>)<\/strong> announced that its <strong>Category 1 pediatric innovative drug<\/strong>, <strong>Retavibart Injection (trade name: Xinduotuo, development code: TNM001)<\/strong>, has been officially approved for marketing in China through the <strong>National Medical Products Administration\u2019s (NMPA)<\/strong> priority review and approval process. The long-acting monoclonal antibody is indicated to prevent <strong>respiratory syncytial virus (RSV)<\/strong> lower respiratory tract infections in neonates and infants entering or born during their first RSV season \u2014 and stands as the <strong>world\u2019s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>Marketing approval via <strong>priority review and approval process<\/strong><\/td><\/tr><tr><td>Product<\/td><td><strong>Retavibart Injection (Xinduotuo; TNM001)<\/strong>, Category 1 pediatric innovative drug<\/td><\/tr><tr><td>Indication<\/td><td>Prevention of RSV lower respiratory tract infections in neonates and infants about to enter or born during their first RSV season<\/td><\/tr><tr><td>Date<\/td><td>04 Sept 2026<\/td><\/tr><tr><td>Developer<\/td><td><strong>Zhuhai Trinomab Biopharmaceutical Co., Ltd.<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Retavibart<\/strong>, a recombinant <strong>long-acting, fully human monoclonal antibody<\/strong> against RSV, independently developed by <strong>Trinomab<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> A conserved epitope on the <strong>pre-fusion (Pre-F) conformation<\/strong> of the RSV fusion protein<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Mediates RSV neutralization and prevents viral fusion with host cells, thereby blocking viral entry and exerting <strong>passive immunoprophylaxis<\/strong><\/li>\n\n\n\n<li><strong>Durability:<\/strong> The <strong>world\u2019s first RSV monoclonal antibody<\/strong> providing up to <strong>nine months of clinical protection data with a single dose<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Approved via NMPA priority review, reflecting the significant unmet need in infant RSV prevention<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-pivotal-phase-3-trial-tnm001-301\" class=\"wp-block-heading\">Clinical Evidence \u2013 Pivotal Phase 3 Trial (TNM001-301)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>150 Days Post-Dose<\/th><th>270 Days Post-Dose<\/th><\/tr><\/thead><tbody><tr><td>Efficacy against medically attended RSV LRTI<\/td><td><strong>71.3%<\/strong><\/td><td><strong>69.9%<\/strong><\/td><\/tr><tr><td>Efficacy against RSV LRTI leading to hospitalization<\/td><td><strong>71.7%<\/strong><\/td><td><strong>69.8%<\/strong><\/td><\/tr><tr><td>Efficacy against severe RSV LRTI (medically attended)<\/td><td><strong>93.9%<\/strong><\/td><td><strong>90.2%<\/strong><\/td><\/tr><tr><td>Efficacy against severe RSV LRTI (leading to hospitalization)<\/td><td><strong>90.1%<\/strong><\/td><td><strong>83.5%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The primary endpoints of the pivotal <strong>TNM001-301<\/strong> Phase 3 study showed that within 150 days post-administration, <strong>Retavibart<\/strong> demonstrated protective efficacy of <strong>71.3%<\/strong> against medically attended RSV lower respiratory tract infections (LRTI) and <strong>71.7%<\/strong> against RSV LRTI leading to hospitalization. Protection against <strong>severe RSV LRTI<\/strong> was even stronger, reaching <strong>93.9%<\/strong> (medically attended) and <strong>90.1%<\/strong> (hospitalization). Crucially, through the <strong>270-day observation period<\/strong>, these protective efficacies were maintained at <strong>69.9%<\/strong> and <strong>69.8%<\/strong> for RSV LRTI and <strong>90.2%<\/strong> and <strong>83.5%<\/strong> for severe RSV LRTI respectively \u2014 validating the single-dose, full-season-plus durability profile.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global first in durability:<\/strong> Up to nine months of single-dose protection distinguishes <strong>Retavibart<\/strong> in the rapidly expanding RSV immunoprophylaxis market, potentially covering more than a typical epidemic season<\/li>\n\n\n\n<li><strong>Severe disease protection:<\/strong> Efficacy exceeding 90% against severe RSV LRTI at both time points addresses the outcomes that drive hospital burden and parental anxiety most directly<\/li>\n\n\n\n<li><strong>Massive addressable market:<\/strong> Virtually all infants encounter RSV in their first years of life, and China\u2019s annual birth cohort represents one of the world\u2019s largest RSV prevention opportunities<\/li>\n\n\n\n<li><strong>Priority review validation:<\/strong> The NMPA\u2019s priority pathway endorsement underscores the drug\u2019s public health significance and accelerates time to first use<\/li>\n\n\n\n<li><strong>Strategic signal:<\/strong> The approval cements <strong>Trinomab Biopharmaceutical\u2019s<\/strong> (SHA: 688806) position in pediatric infectious disease prevention, a category increasingly prioritized by Chinese regulators and payers<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding commercialization plans, market uptake and reimbursement outcomes are forward-looking and subject to risks and uncertainties, including pricing policy, competitive developments and real-world adoption. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/688806_20260904_RRM7.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688806_20260904_RRM7.\"><\/object><a id=\"wp-block-file--media-84c146b6-2740-4272-b86c-6f79d57fe290\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/688806_20260904_RRM7.pdf\">688806_20260904_RRM7<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/688806_20260904_RRM7.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-84c146b6-2740-4272-b86c-6f79d57fe290\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[15,4867,4928],"class_list":["post-78798","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-product-approvals","tag-sha-688806","tag-trinomab-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug, Retavibart Injection (trade name: Xinduotuo, development code: TNM001), has been officially approved for marketing in China through the National Medical Products Administration\u2019s (NMPA) priority review and approval process. The long-acting monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in neonates and infants entering or born during their first RSV season \u2014 and stands as the world\u2019s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78798\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo\" \/>\n<meta property=\"og:description\" content=\"Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug, Retavibart Injection (trade name: Xinduotuo, development code: TNM001), has been officially approved for marketing in China through the National Medical Products Administration\u2019s (NMPA) priority review and approval process. The long-acting monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in neonates and infants entering or born during their first RSV season \u2014 and stands as the world\u2019s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78798\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T08:44:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T08:44:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78798#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78798\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo\",\"datePublished\":\"2026-09-04T08:44:52+00:00\",\"dateModified\":\"2026-09-04T08:44:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78798\"},\"wordCount\":580,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Product approvals\",\"SHA: 688806\",\"Trinomab Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78798#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78798\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78798\",\"name\":\"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T08:44:52+00:00\",\"dateModified\":\"2026-09-04T08:44:53+00:00\",\"description\":\"Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug, Retavibart Injection (trade name: Xinduotuo, development code: TNM001), has been officially approved for marketing in China through the National Medical Products Administration\u2019s (NMPA) priority review and approval process. The long-acting monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in neonates and infants entering or born during their first RSV season \u2014 and stands as the world\u2019s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78798#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78798\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78798#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo - Insight, China&#039;s Pharmaceutical Industry","description":"Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug, Retavibart Injection (trade name: Xinduotuo, development code: TNM001), has been officially approved for marketing in China through the National Medical Products Administration\u2019s (NMPA) priority review and approval process. The long-acting monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in neonates and infants entering or born during their first RSV season \u2014 and stands as the world\u2019s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78798","og_locale":"en_US","og_type":"article","og_title":"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo","og_description":"Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug, Retavibart Injection (trade name: Xinduotuo, development code: TNM001), has been officially approved for marketing in China through the National Medical Products Administration\u2019s (NMPA) priority review and approval process. The long-acting monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in neonates and infants entering or born during their first RSV season \u2014 and stands as the world\u2019s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose.","og_url":"https:\/\/flcube.com\/?p=78798","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T08:44:52+00:00","article_modified_time":"2026-09-04T08:44:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78798#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78798"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo","datePublished":"2026-09-04T08:44:52+00:00","dateModified":"2026-09-04T08:44:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78798"},"wordCount":580,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Product approvals","SHA: 688806","Trinomab Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78798#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78798","url":"https:\/\/flcube.com\/?p=78798","name":"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T08:44:52+00:00","dateModified":"2026-09-04T08:44:53+00:00","description":"Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug, Retavibart Injection (trade name: Xinduotuo, development code: TNM001), has been officially approved for marketing in China through the National Medical Products Administration\u2019s (NMPA) priority review and approval process. The long-acting monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in neonates and infants entering or born during their first RSV season \u2014 and stands as the world\u2019s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78798#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78798"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78798#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Trinomab\u2019s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78798"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78798\/revisions"}],"predecessor-version":[{"id":78802,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78798\/revisions\/78802"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}